Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...

The 5-year unadjusted cumulative incidence of death-censored graft loss from a cohort matched on survival time before GLP-1 RA initiation was 6.0% for GLP-1 RA users and 10.7% for nonusers.

HealthDay News — Preoperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is not associated with short-term postoperative aspiration pneumonia, according to a study published online March ...

Initial reports of increased suicidality in GLP-1 RA users compared with the general population raised concerns about the risk for this rare but serious adverse event, given the rising popularity ...

Patients who continued Ozempic through total joint arthroplasty had the highest risk for complications. (HealthDay News) — Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment ...

GLP-1 RA use linked to lower risks for myelodysplastic syndromes, myeloproliferative neoplasms compared with metformin ...

Semaglutide's main competitor in the GLP-1 RA therapy market is Eli Lilly's ... ZLDPF), Terns Pharmaceuticals (TERN) and Structure Therapeutics (GPCR).

Adults aged 66 years or older with T2D initiating treatment with a GLP-1 RA were propensity score-matched to those initiating treatment with an SGLT-2i (14,665 matched pairs) or a DPP-4i (13,711 ...

using its long-acting GLP-1 Receptor Agonist [GLP-1 RA] for the treatment of patients with obesity. It is currently in the process of treating obesity patients using the very same drug in an ...

GLP-1 RA use is associated with better graft and patient survival among kidney transplant recipients with diabetes.